Histogen Announces $4.75 Million Private Placement
SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage company…
Year: 2022
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call
ARLINGTON, Mass., March 23, 2022 (GLOBE NEWSWIRE) — Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical…
Ventyx Biosciences Reports Full Year 2021 Financial Results and Highlights Recent Corporate Progress
Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022…
Vallon Pharmaceuticals to Participate at the 5th Annual Neuroscience Innovation Forum
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry…
Synthetic Biologics Announces Management Transitions in Support of Strategic Transformation
-Frank Tufaro, Ph.D., appointed as Chief Operating Officer of Synthetic Biologics, transitioning from Chief Operating…
AccuStem Sciences, Inc. Announces DTC Eligibility
LONDON and PHOENIX, March 23, 2022 (GLOBE NEWSWIRE) — AccuStem Sciences, Inc. (OTC Pink: ACUT),…
Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors
MALVERN, Pa., March 23, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biotechnology company…
VectivBio Presents Preclinical Data Supporting Apraglutide for Treatment of Acute Graft-Versus-Host Disease at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation
— Apraglutide, a next-generation GLP-2 analog, protected against chemotherapy-induced gastrointestinal (GI) damage and improved survival…
Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions
Results show the potential in the use of PLX-R18 for meaningful advantage over other existing…
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability Results…
XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection
Compositions and Methods for Enhancing Anti-Viral Therapies CALGARY, Alberta, March 23, 2022 (GLOBE NEWSWIRE) —…
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease
100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified…
Roche donates additional medicines and diagnostics for Ukraine
Basel, 23 March 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the donation…
Immatics Announces Full Year 2021 Financial Results and Corporate Update
IMA203 TCR-T candidate targeting PRAME demonstrated a 50% objective response rate across different solid tumor…
Freeline to Participate in Upcoming Investor Conferences
LONDON, March 23, 2022 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company”…
VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update
OVAL top-line data for ofra-vec progression free survival (PFS) primary endpoint expected in 2H 2022;…
Plus Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV), a U.S. clinical-stage pharmaceutical…
CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq:…
atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq:…
Verizon and Snap Inc. put Cirque du Soleil – ‘O’ in the palm of your hand
Exclusive to Verizon customers, 5G Ultra Wideband and augmented reality make Las Vegas-based performance accessible…